New method to modulate the immune system for Type 1 diabetes
Official title: New approach for immune modulation against T1D
Funded at Evoq Therapeutics, INC. · NIH-10931397 · Data updated 2026-11-12
This study is testing a new treatment for Type 1 diabetes that aims to help your immune system work better by encouraging the growth of special cells that can protect your insulin-producing cells, using a unique delivery method to make it safe and effective for people with T1D.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Evoq Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | September 20, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $756,491 |
| NIH project number | 5R44DK135218-02 |
| Project ID | NIH-10931397 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Type 1 diabetes, particularly those experiencing challenges with current management strategies.
✕Less likely to help
Patients with Type 1 diabetes who have already developed severe complications or those with other autoimmune diseases may not benefit from this research.
What this research studies
This research focuses on developing a novel immunotherapy approach for Type 1 diabetes (T1D), an autoimmune condition that leads to the destruction of insulin-producing cells in the pancreas. The study aims to induce regulatory T cells (Tregs) that can help restore immune balance and prevent the progression of T1D. Researchers are utilizing synthetic high-density lipoprotein NanoDiscs designed to target lymph nodes and promote a robust Treg response. This innovative method seeks to provide a safe and effective treatment option for individuals suffering from T1D.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that helps manage or potentially reverse Type 1 diabetes.
How similar studies have gone: Previous research has shown promise in using immunotherapy approaches to modulate immune responses in autoimmune diseases, indicating potential for success with this novel method.
Where this research is happening
-
Evoq Therapeutics, INC.
Ann Arbor, United States Active
Researchers
- Principal investigator: Daniel, Weston — Evoq Therapeutics, INC.
- Study coordinator: Daniel, Weston
Related research
Other NIH-funded projects on the same topics.
-
NanoDiscs: a new way to calm the immune system in celiac disease
A new, protein-like particle called NanoDiscs is being developed to deliver safe targets to the immune system in people with celiac disease, with the goal of reducing reactions to gluten.
-
New Treatment for MOG Antibody Condition
This research is developing a new, targeted treatment for people living with MOG antibody disease, a rare neurological condition.
-
New treatment for MOG antibody disease using nanoparticles
This study is testing a new treatment for MOG antibody disease that uses tiny particles to help your immune system learn to tolerate the disease better, with the hope of providing a safer option than current medications like steroids.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.